Myeloid Therapeutics Revenue and Competitors

Location

#3633

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Myeloid Therapeutics's estimated annual revenue is currently $4.7M per year.(i)
  • Myeloid Therapeutics's estimated revenue per employee is $77,500
  • Myeloid Therapeutics's total funding is $123M.

Employee Data

  • Myeloid Therapeutics has 61 Employees.(i)
  • Myeloid Therapeutics grew their employee count by 20% last year.

Myeloid Therapeutics's People

NameTitleEmail/Phone
1
CEO & Co-FounderReveal Email/Phone
2
Chief Medical OfficerReveal Email/Phone
3
VP Translational ResearchReveal Email/Phone
4
VP Discovery ResearchReveal Email/Phone
5
VP, Head CMCReveal Email/Phone
6
VP, ClinicalReveal Email/Phone
7
SVP FinanceReveal Email/Phone
8
Associate Director, CMC OperationsReveal Email/Phone
9
Chief Medical OfficerReveal Email/Phone
10
Snr. Director, Discovery ResearchReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Myeloid Therapeutics?

Myeloid Therapeutics is an immunology company focused on combining biology insights with cutting-edge technologies to harness myeloid cells and eradicate cancer and other diseases. We’re passionate about scientific inquiry, collaborating to solve big clinical problems, and most of all, helping patients. Myeloid is powered by our founders – a group of world-leading scientists whose expertise spans oncology, immunology, mRNA biology, cell therapy, synthetic biology, and gene delivery. And we are working to build a team of talented, driven scientists and other biotech industry experts, who will turn these discoveries into novel, lifesaving treatments for patients. Our ATAKTM platform integrates the accumulated know-how and experience of our founders and our growing research team, to deliver new products that reprogram innate immune cells to eradicate disease. We have built a platform manufacturing process that reduces cell handling to less than one day, and supports the rapid translation of the company’s lead assets to the clinic: MT-101 for peripheral and cutaneous forms of T cell Lymphoma, MT-102 for HER2 expressing solid tumors, MT-103 for TROP2 expressing solid tumors, and MT-201, our primed monocyte that stimulates T cells to fight glioblastoma. We expect to initiate clinical trials for several of these product candidates in the first half of 2021, a mere 18-months from our founding. We invite you to join us on this journey – patients are waiting. – Daniel Getts, CEO

keywords:N/A

$123M

Total Funding

61

Number of Employees

$4.7M

Revenue (est)

20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Myeloid Therapeutics News

2022-04-06 - Myeloid Therapeutics Presents Late-Breaking Data at AACR 2022 ...

("Myeloid"), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today presented new late...

2022-03-30 - Myeloid and Prime Medicine partner to work on gene insertion

The technology can be used alongside Prime Editing to simplify ex vivo and in vivo cell therapy delivery. Myeloid Therapeutics and Prime...

2022-03-22 - Myeloid Therapeutics and Prime Medicine Enter Into Exclusive ...

Myeloid Therapeutics is a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases. Integrating...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$13.9M619%N/A
#2
$8M6113%N/A
#3
$7.7M6145%N/A
#4
$7.1M61-3%N/A
#5
$8.4M622%N/A